Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma’s (ASND) Investment Narrative?

• Ascendis Pharma recently reported past Week 52 topline results from its Phase 2 COACH trial, showing that once-weekly TransCon CNP plus TransCon hGH in children with achondroplasia delivered durable growth, improved body proportionality and arm span, and a safety profile consistent with the monotherapies.
• The data, alongside TransCon CNP’s ongoing FDA Priority Review for achondroplasia, highlights the company’s ambition to position TransCon CNP as a backbone therapy targeting the condition’s underlying biology.
• We’ll now examine how these COACH trial combination results, particularly the improved growth and proportionality outcomes, reshape Ascendis Pharma’s investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Ascendis Pharma Investment Narrative Recap

To own Ascendis Pharma, you need to believe in its TransCon platform becoming a suite of standard-of-care therapies across multiple endocrine and rare disease indications, while the company manages high spending and execution risk. The COACH Week 52 data strengthen the achondroplasia story, but the key near term catalyst remains the FDA Priority Review decision on TransCon CNP for monotherapy, and the largest risk is still that any regulatory setback or label limitation could slow the next leg of growth.

Among recent announcements, the company’s plan to present a 2026 roadmap at the J.P. Morgan Healthcare Conference stands out in light of the COACH update, because it frames how management prioritizes TransCon CNP’s potential approval alongside ongoing commercialization of SKYTROFA and YORVIPATH. That context matters for investors tracking how new indications might balance the pressures of elevated R&D and SG&A spending while the current portfolio scales.

Yet beneath the promise of combination therapy, investors should be aware of how dependent the growth story is on future regulatory success and…

Read the full narrative on Ascendis Pharma (it’s free!)

Ascendis Pharma’s narrative projects €2.2 billion in revenue and €826.6 million in earnings by 2028.

Uncover how Ascendis Pharma’s forecasts yield a $260.26 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community range from US$222 to US$939 per share, underlining how differently people see Ascendis Pharma’s potential. You should weigh that variety of views against the fact that future growth still leans heavily on successful TransCon CNP approvals and label outcomes, which could materially affect how the business performs over time.

Explore 4 other fair value estimates on Ascendis Pharma – why the stock might be worth over 4x more than the current price!

Build Your Own Ascendis Pharma Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

No Opportunity In Ascendis Pharma?

Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com